

Research article

Open Access

Effects of nimesulide on kainate-induced in vitro oxidative damage in rat brain homogenates

Eduardo Candelario-Jalil* and Olga Sonia León

Address: Department of Pharmacology, University of Havana (CIEB-IFAL), Apartado Postal 6079, Havana City 10600, Cuba

Email: Eduardo Candelario-Jalil* - ecjalil@infomed.sld.cu; Olga Sonia León - olga@cieb.sld.cu

* Corresponding author

Published: 14 June 2003

Received: 13 April 2003

BMC Pharmacology 2003, 3:7

Accepted: 14 June 2003

This article is available from: <http://www.biomedcentral.com/1471-2210/3/7>

© 2003 Candelario-Jalil and Sonia León; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: The cyclooxygenase-2 inhibitor nimesulide is able to reduce kainate-induced oxidative stress in vivo. Here we investigate if this effect is mediated by the direct antioxidant properties of nimesulide using a well-characterized in vitro model of kainate toxicity.

Results: Exposure of rat brain homogenates to kainate (12 mM) caused a significant ($p < 0.01$) increase in the concentrations of malondialdehyde and 4-hydroxy-alkenals and a significant ($p < 0.01$) decrease in sulfhydryl levels. High concentrations of nimesulide (0.6–1.6 mM) reduced the extent of lipid peroxidation and the decline in both total and non-protein sulfhydryl levels induced by kainate in a concentration-dependent manner.

Conclusions: Our results suggest that the neuroprotective effects of nimesulide against kainate-induced oxidative stress in vivo are not mediated through its direct free radical scavenging ability because the concentrations at which nimesulide is able to reduce in vitro kainate excitotoxicity are excessively higher than those attained in plasma after therapeutic doses.

Background

Nimesulide (N-(4-nitro-2-phenoxy-phenyl)-methanesulfonamide) is a non-steroidal anti-inflammatory drug with potent anti-inflammatory, antipyretic and analgesic properties which is well tolerated gastrointestinally [1]. Nimesulide is considered a selective cyclooxygenase-2 (COX-2) inhibitor [2,3]. Although inhibition of prostanooids synthesis is a key effect of this drug, various non-prostaglandin mechanisms have been proposed to explain its mode of action: inhibition of 1) histamine release and activity [4], 2) cytokine release [5], 3) platelet-activating factor synthesis [6,7] and 4) phosphodiesterase

type IV activity [9]. Moreover, nimesulide decreases the production of the superoxide anion ($O_2^{\bullet-}$) by polymorphonuclear leukocytes [8,10].

Maffei-Facino and co-workers [11] demonstrated the direct free radical scavenging activity of nimesulide. In two different cell free systems, nimesulide acts as a preventive antioxidant by specifically quenching the hydroxyl radical (HO^{\bullet}), the highly reactive species that, by promoting hydrogen abstraction from polyunsaturated fatty acids (PUFA), leads to cellular damage mediated by peroxidation of membrane phospholipids.

Kainic acid (2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine) is a non-degradable analog of glutamate isolated from the seaweed *Digenea simplex* with potent neuroexcitatory and neurotoxic properties [12]. Those effects seem to be mediated by a subclass of non-N-methyl-D-aspartate excitatory amino acid receptors [13]. It was found that free radical generation is associated with excitatory amino acid-induced brain injury [14]. Kainate has been shown to generate free radicals when added in vitro to rat cerebellar cell cultures [15] and in gerbil brain, following its systemic administration [16]. Also, reactive oxygen species were detected when kainate was added to isolated synaptoneurosomes derived from rat cerebral cortex [17]. Furthermore, it was demonstrated previously [18] that the addition of kainate to mouse disrupted brain cells caused a concentration-dependent increase in lipid peroxidation.

Recently, we have found that kainate-induced excitotoxicity, with the subsequent oxidative damage, is significantly reduced by the administration of nimesulide at a clinically relevant dose in the rat hippocampus [19]. In addition, we also found a marked neuroprotective effect of nimesulide against hippocampal neuronal damage following global cerebral ischemic brain damage in gerbils, a type of injury in which excitotoxicity plays a key role [20].

Given that the effects of nimesulide reducing oxidative damage in vivo might be attributed to its direct antioxidant properties, the aim of the present study was to determine whether nimesulide could attenuate the oxidative damage seen after the in vitro exposure of disrupted brain cell homogenates to kainate.




Figure 1
Effect of different concentrations (1, 6 and 12 mM) of kainic acid (KA) on malonaldehyde (MDA) and 4-hydroxyalkenals (4-HDA) concentrations in perfused rat brain homogenates following 20 min incubation. Values are means \pm SEM of 3 experiments. Significant differences were determined by one-way ANOVA followed by Student-Newman-Keuls post-hoc test. *P < 0.05 and **P < 0.01 with respect to control.

Table 1: Effect of different concentrations (1, 6 and 12 mM) of kainic acid (KA) on total sulfhydryl groups (TSH) and non-protein sulfhydryl groups (NPSH) following 20 min incubation with rat brain homogenates.

	TSH (nmol/mg protein)	NPSH (μ mol/g tissue)
Control	23.97 \pm 0.25	1.85 \pm 0.03
KA (1 mM)	22.97 \pm 0.38	1.77 \pm 0.05
KA (6 mM)	20.90 \pm 0.27 *	1.65 \pm 0.05 *
KA (12 mM)	19.25 \pm 0.35 **	1.61 \pm 0.04 **

Values are means \pm SEM of 3 experiments. *P < 0.05 and **P < 0.01 with respect to control.

Results

The exposure of rat brain homogenates to different concentrations of kainate caused a concentration-dependent increase in the levels of MDA and 4-HDA compared to those in control samples (Fig. 1). On the other hand, kainate produced a significant decrease in TSH and NPSH levels, specially the highest concentrations (6 and 12 mM) as shown in Table 1. Because of the high oxidative damage induced by 12 mM kainate, this concentration was chosen for subsequent studies.

When kainate (12 mM) was added to the reaction mixture together with different concentrations of nimesulide (ranging from 0.6 to 1.6 mM) the increase in lipid peroxidation was reduced in a concentration-dependent manner (Fig. 2). In a similar way, nimesulide was able to protect sulfhydryl groups from kainate-induced oxidative damage (Table 2). The lowest concentrations of nimesulide tested (from 0.1 to 0.4 mM) were unable to confer protection against lipid peroxidation and sulfhydryl groups oxidation as shown in Fig. 2 and Table 2.

We also employed the widely used powerful antioxidant Trolox C (6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; a water-soluble analogue of α -tocopherol) as a control and found that Trolox C at concentrations as low as 50–100 μ M was able to significantly ($p < 0.05$) reduce oxidative damage induced by 12 mM kainate (data not shown).

In addition, in the absence of kainate, the exposure of brain homogenates to the different concentrations of nimesulide tested did not modify MDA and 4-HDA or sulfhydryl group levels, which were not significantly changed as compared to those in control samples (data not shown).

Discussion

Results from these studies show that kainate-induced oxidative damage as measured by the increase in the concentrations of MDA and 4-HDA and by the decrease in




Figure 2
Effect of Nimesulide (NIM) on malonaldehyde (MDA) and 4-hydroxy-alkenals (4-HDA) concentrations in perfused rat brain homogenates following 20 min incubation with 12 mM kainic acid (KA). Values are means ± SEM of 3 experiments. Significant differences were determined by one-way ANOVA followed by Student-Newman-Keuls post-hoc test. *P < 0.05 and **P < 0.01 with respect to KA 12 mM.

Table 2: Effect of nimesulide (NIM) on total sulfhydryl groups (TSH) and non-protein sulfhydryl groups (NPSH) following 20 min incubation with 12 mM kainic acid (KA).

	TSH (nmol/mg protein)	NPSH (μmol/g tissue)
Control	23.97 ± 0.25 **	1.85 ± 0.03 **
KA	19.25 ± 0.35	1.61 ± 0.04
KA + NIM (0.1 mM)	18.72 ± 0.38	1.57 ± 0.03
KA + NIM (0.2 mM)	20.21 ± 0.56	1.64 ± 0.03
KA + NIM (0.4 mM)	20.25 ± 0.35	1.71 ± 0.02
KA + NIM (0.6 mM)	21.96 ± 0.46 *	1.76 ± 0.03 *
KA + NIM (0.8 mM)	22.67 ± 0.30 **	1.76 ± 0.01 *
KA + NIM (1.0 mM)	23.14 ± 0.15 **	1.78 ± 0.02 *
KA + NIM (1.2 mM)	23.03 ± 0.30 **	1.81 ± 0.04 **
KA + NIM (1.4 mM)	23.68 ± 0.25 **	1.79 ± 0.03 **
KA + NIM (1.6 mM)	24.03 ± 0.31 **	1.81 ± 0.02 **

Values are means ± SEM of 3 experiments. Significant differences were determined by one-way ANOVA followed by Student-Newman-Keuls post-hoc test: *P < 0.05 and **P < 0.01 with respect to KA 12 mM.

sulfhydryl groups levels in disrupted cell homogenates from rat brain is markedly inhibited by high concentrations of nimesulide.

Brain cells are at particular risk from free radical damage because of their high content of iron and PUFA, the latter being a substrate for lipid peroxidation, and because of their relatively deficient antioxidant defense mechanisms [21].

Our results are consistent with previous reports which show that kainate-induced death of cerebellar neurons is prevented either by inhibiting the enzyme xanthine oxidase, a cellular source of superoxide anions, or by the addition of free radical scavengers to the culture medium [15]. The generation of free radicals by kainic acid and its correlation with excitotoxicity have been proposed by several groups [15,16,18,22]. The ability of kainate to induce lipid peroxidation was proven in brain by measuring the change in conjugated diene and lipid hydroperoxide concentrations after exposure of cerebellar granular cells to the excitotoxin [22]. Furthermore, the addition of kainate to mouse disrupted brain cells has been shown to cause a concentration-related increase in thiobarbituric acid-reactive substances generation [18].

It is generally accepted that neuronal degeneration after kainic acid administration is associated with a depletion of ATP levels and accumulation of [Ca²⁺]_i. The increase in [Ca²⁺]_i may trigger Ca²⁺-activated protease to convert xanthine dehydrogenase to xanthine oxidase with the simultaneous formation of free radicals [15]. In addition, xanthine dehydrogenase could be converted to xanthine oxidase by sulfhydryl oxidation [23]. On the other hand, the increase in [Ca²⁺]_i may activate enzymes such as phospholipase A₂ which hydrolyzes the membrane phospholipids to release PUFA leading to free radical generation [15].

In our previous study we found a significant neuroprotective effect of the cyclooxygenase-2 inhibitor nimesulide against the depletion of reduced glutathione and increase in lipid peroxidation at a therapeutically relevant dose (6 mg/kg; i.p) [19]. Similarly, in the present study nimesulide was able to protect against in vitro kainate-induced sulfhydryl group oxidation and lipid peroxidation, but this effect was observed only at high concentrations, which are unlikely to be attained in plasma after therapeutic doses. Even when the effects of nimesulide against kainate excitotoxicity in vivo and in vitro are similar, the mechanisms of nimesulide neuroprotection in vivo are quite different from the in vitro effects on measures of oxidative injury, because in the in vitro model (homogenates of rat brain), nimesulide might be acting directly as a scavenger of kainate-generated reactive oxygen species, producing a concomitant reduction in markers of oxidative stress. Unlike the in vitro situation, nimesulide treatment afforded a neuroprotective effect against kainate-induced in vivo oxidative stress in the rat hippocampus, probably acting through inhibition of cyclooxygenase-2, which is now considered a key cellular source of free radicals in the injured brain [24]. It is important to emphasize that several studies have found a marked expression of cerebral cyclooxygenase-2 mRNA and protein following the systemic administration of kai-

nate [25–27]. The induction of cyclooxygenase-2 expression parallels the appearance of neuronal apoptotic features in cell types affected by kainate, and excitotoxic neuronal death *in vitro* is accompanied by a selective elevation in cyclooxygenase-2 mRNA, indicating that cyclooxygenase-2 may be involved in pathways leading to neuronal death [28]. In support of this, results from our previous work indicated that the induction of cyclooxygenase-2 is involved in kainate-mediated free radicals formation [19]. Based on the pharmacological effects of nimesulide, additional mechanisms could account for the neuroprotection conferred by nimesulide against *in vivo* kainate excitotoxicity, such as inhibition of pro-inflammatory cytokines production, reduction in nitric oxide generation and blockade of apoptotic pathways, but these effects should be confirmed.

Several findings support the antioxidant activity of nimesulide [11,29,30]. Using the *in vitro* model of NADPH-supported lipid peroxidation in rat liver microsomes, nimesulide and its metabolites significantly inhibited MDA formation in a concentration-dependent manner [29]. Furthermore, using an *in vitro* assay based on the oxidation of phosphatidylcholine liposomes (exposed to a flux of hydroxyl radicals generated by water sonolysis), nimesulide exhibited a remarkable scavenging activity against free radicals at concentrations easily attainable *in vivo* (4.92 μM). Maffei-Facino and co-workers [11] investigated the superoxide anion ($\text{O}_2^{\bullet-}$) and hydroxyl radical (HO^{\bullet}) scavenging activities of nimesulide and its main metabolite 4-hydroxynimesulide, using the Electron Spin Resonance (ESR) spectroscopy with the spin trapping technique. According to their results, 4-hydroxynimesulide is a good scavenger of both oxygen free radicals and its rate constant of reaction with HO^{\bullet} is $8.9 \times 10^{10} \text{ M}^{-1} \text{ s}^{-1}$. Nimesulide, which has been shown by ESR to be inactive as a $\text{O}_2^{\bullet-}$ quencher, has a rate constant of reaction with HO^{\bullet} slightly greater than that of its metabolite ($3.3 \times 10^{11} \text{ M}^{-1} \text{ s}^{-1}$). Taken together, all these studies indicate that antioxidant properties might account for the pharmacological effects of nimesulide.

In the present study, nimesulide conferred a concentration-dependent protection against kainate-induced peroxidation of membrane phospholipids when added together with kainate. The lowest concentrations of nimesulide (0.1 to 0.4 mM) were unable to reduce lipid peroxidation (Fig. 2). Similarly, only the highest concentrations of nimesulide (from 0.6 to 1.6 mM) were able to protect sulfhydryl groups from oxidation, suggesting that relatively high concentrations of nimesulide are able to protect against *in vitro* kainate toxicity.

Conclusions

In summary, since the concentrations of nimesulide in plasma are estimated to be around 10–20 μM after the administration of clinically used doses [3], results from the present study suggest that the *in vivo* neuroprotective effects of nimesulide against kainate excitotoxicity are not mediated by direct free radical scavenging ability of this compound because only excessively high concentrations (0.6–1.6 mM) were proven to reduce kainate-induced oxidative stress in our study. It is much more likely that the effects of nimesulide against kainate-induced oxidative damage [19] are mediated by the inhibition of cyclooxygenase-2, a key source of free radicals under damaging conditions to the brain [24].

Methods

Chemicals

All reagents were of the highest quality available. Kainic acid and 5,5'-dithiobis-(2-nitrobenzoic acid) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Nimesulide was kindly provided by Gautier-Bagó Laboratories (Buenos Aires, Argentina). The Bioxytech LPO-586 kit for lipid peroxidation was obtained from Cayman Chemical Co. (Ann Arbor, MI, USA).

Animals

Adult male Sprague-Dawley rats (body weight 200–250 g; $n = 12$) were obtained from CENPALAB (Havana, Cuba) and housed in Plexiglass cages (4 per cage) and maintained in an air-filtered and automatic temperature controlled (20–22°C) room with a relative humidity of 50–52%. Rats were fed with standard laboratory chow and water *ad libitum* and were kept under artificial light-dark cycle of 12 h.

Solutions and range of concentrations

Nimesulide was dissolved in absolute ethanol (when added to the brain homogenate, the final alcohol concentration was 1%) and added as one of nine different concentrations (0.1, 0.2, 0.4, 0.6, 0.8, 1, 1.2, 1.4, and 1.6 mM) to the incubation mixture. The exposure of rat brain homogenates to 1% ethanol was proven not to produce any effect [31]. Kainic acid was dissolved in Tris-HCl buffer (20 mM, pH 7.4) and added in 3 different concentrations (1, 6 and 12 mM) to the homogenate.

Brain sample preparation

Rats were anesthetized with diethyl ether and subjected to intracardiac perfusion using a peristaltic pump (DIDT-CNIC Peristaltic, Cuba) with ice-cold saline in order to eliminate the excess of iron (bound to hemoglobin) that may artificially increase free radical generation. Brains were collected and immediately stored at -70°C.

Lipid peroxidation assay

This assay was conducted as previously reported [31]. Briefly, twelve brains were pooled and homogenized in ice-cold Tris-HCl buffer (20 mM, pH 7.4) with a motor driven homogenizer (Edmund Bühler, Germany) to produce a 1/10 homogenate. Aliquots of the homogenates were incubated in a shaking water bath for 20 min at 37°C with different concentrations of kainic acid and with or without nine different concentrations of nimesulide (from 0.1 to 1.6 mM). Moreover, nimesulide (at the concentrations tested) was added to the homogenate without kainate. After the incubation time, the reaction was stopped by cooling the samples in ice for 10 min. Thereafter, the samples were centrifuged at 12 000 × g for 5 min. The supernatant was collected and immediately tested for lipid peroxidation and sulfhydryl groups.

Lipid peroxidation was assessed by measuring the concentration of malonaldehyde (MDA) and 4-hydroxy-alkenals (4-HDA). These constituents are formed, for the most part, from the peroxidation of PUFA and are widely used as an index of lipid peroxidation [32]. The Bioxytech LPO-586 kit was used for these measurements; this kit takes advantage of a chromogenic reagent (N-methyl-2-phenylindole) which reacts with MDA and 4-HDA at 45°C yielding a stable chromophore with maximal absorbance at a wavelength of 586 nm. This wavelength and the low temperature of incubation used in this procedure minimize interferences and undesirable artifacts [32].

Sulfhydryl groups assay

Total (TSH) and non-protein (NPSH) sulfhydryl groups determinations were performed according to the method of Sedlak and Lindsay [33] using the Ellman's reagent.

Protein assay

Total protein concentration was determined using the Coomassie Blue method [34] with bovine serum albumin as standard.

Statistical analysis

Results are presented as mean ± SEM (standard error of means). All data were analyzed by one-way analysis of variance (ANOVA). If the F values were significant, the Student-Newman-Keuls post-hoc test was used to compare groups. The level of significance was accepted at $p < 0.05$.

List of Abbreviations

O₂^{•-}, superoxide anion; HO•, hydroxyl radical; PUFA, polyunsaturated fatty acids; MDA, malonaldehyde; 4-HDA, 4-hydroxy-alkenals; TSH, total sulfhydryl groups; NPSH, non-protein sulfhydryl groups; COX-2, cyclooxygenase-2.

Authors' contributions

Author 1 carried out the experimental procedures including the biochemical analyses, participated in the design of the study, performed the statistical analysis and drafted the manuscript. Author 2 participated in the design of the study and revised the manuscript.

References

- Davis R and Brogden RN: **Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy** *Drugs* 1994, **48**:431-454.
- Famaey JP: **In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview** *Inflamm Res* 1997, **46**:437-446.
- Rabasseda X: **Nimesulide: a selective cyclooxygenase 2 inhibitor antiinflammatory drug** *Drugs Today* 1996, **32**(Suppl 1):1-23.
- Rossoni G, Berti F, Buschi LM and Della Bella D: **New data concerning the anaphylactic and antihistaminic activity of nimesulid** *Drugs* 1993, **46**(Suppl 1):22-28.
- Ferreira SH: **The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesic** *Drugs* 1993, **46**(Suppl 1):1-9.
- Tool AT and Verhoeven AJ: **Inhibition of the production of platelet activating factor and of leukotriene B4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate** *Arzneimittel Forschung* 1995, **45**:1110-1114.
- Verhoeven AJ, Tool AT, Kuijpers TW and Roos D: **Nimesulide inhibits platelet-activating factor synthesis in activated human neutrophil** *Drugs* 1993, **46**(Suppl 1):52-58.
- Bevilacqua M, Vago T, Baldi G, Renesto E, Dallegri F and Norbiato G: **Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV** *Eur J Pharmacol* 1994, **268**:415-423.
- Ottonello L, Dapino P, Pastorino G, Montagnani G, Gatti F, Guidi G and Dallegri F: **Nimesulide as a downregulator of the activity of the neutrophil myeloperoxidase pathway. Focus on the histoprotective potential of the drug during inflammatory processes** *Drugs* 1993, **46**(Suppl 1):29-33.
- Capecci PL, Ceccatelli L, Beermann U, Laghi Pasini F and Di Perri T: **Inhibition of neutrophil function in vitro by nimesulide. Preliminary evidence of an adenosine-mediated mechanism** *Arzneimittel Forschung* 1993, **43**:992-996.
- Maffei-Facino R, Carini M, Aldini G, Saibene L and Morelli R: **Differential inhibition of superoxide, hydroxyl and peroxy radicals by nimesulide and its main metabolite 4-hydroxynimesulid** *Arzneimittel Forschung* 1995, **45**:1102-1109.
- Coyle JT and Schwarcz R: **Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea** *Nature* 1976, **263**:244-246.
- Coyle JT: **Neurotoxic action of kainic acid. Short review** *J Neurochem* 1983, **41**:1.
- Dutrait N, Culcasi M, Cazeville C, Pietri S and Müller A: **Calcium-dependent free radical generation in cultured retinal neurons injured by kainate** *Neurosci Lett* 1995, **198**:13-16.
- Dykens JA, Stern A and Trenkner E: **Mechanisms of kainate toxicity to cerebellar neurons in vitro is analogous to reperfusion tissue injury** *J Neurochem* 1987, **49**:1222-1228.
- Sun AY, Cheng Y, Bu Q and Oldfield F: **The biochemical mechanism of the excitotoxicity of kainic acid** *Mol Chem Neuropathol* 1992, **17**:51-63.
- Bondy SC and Lee DK: **Oxidative stress induced by glutamate receptor agonists** *Brain Res* 1993, **610**:229-233.
- Bose R, Schnell L, Pinsky C and Zitko V: **Effects of excitotoxins on free radical indices in mouse brain** *Toxicol Lett* 1992, **60**:211-219.
- Candelario-Jalil E, Ajamieh HH, Sam S, Martínez G and León OS: **Nimesulide limits kainate-induced oxidative damage in the rat hippocampus** *Eur J Pharmacol* 2000, **390**:295-298.
- Candelario-Jalil E, Alvarez D, González-Falcón A, García-Cabrera M, Martínez-Sánchez G, Merino N, Giuliani A and León OS: **Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia** *Eur J Pharmacol* 2002, **453**:189-195.

21. Halliwell B and Gutteridge JMC: **Oxygen radicals and the nervous system** *Trends Neurosci* 1985, **8**:22-29.
22. Puttfarcken PS, Getz RL and Coyle JT: **Kainic acid-induced lipid peroxidation: protection with butylated hydroxytoluene and U7851F in primary cultures of cerebellar granule cells** *Brain Res* 1993, **624**:223-232.
23. Hamer I, Wattiaux R and Wattiaux CS: **Deleterious effects of xanthine oxidase on rat liver endothelial cells after ischemia/reperfusion** *Biochim Biophys Acta* 1995, **1269**:145-152.
24. Hurley SD, Olschowka JA and O'Banion MK: **Cyclooxygenase inhibition as a strategy to ameliorate brain injury** *J Neurotrauma* 2002, **19**:1-15.
25. Sanz O, Estrada A, Ferrer I and Planas AM: **Differential cellular distribution and dynamics of HSP70, cyclooxygenase-2, and c-Fos in the rat brain after transient focal ischemia or kainic acid** *Neuroscience* 1997, **80**:221-232.
26. Sandhya TL, Ong WY, Horrocks LA and Farooqui AA: **A light and electron microscopic study of cytoplasmic phospholipase A2 and cyclooxygenase-2 in the hippocampus after kainate lesions** *Brain Res* 1998, **788**:223-231.
27. Hashimoto K, Watanabe K, Nishimura T, Iyo M, Shirayama Y and Minabe Y: **Behavioral changes and expression of heat shock protein HSP-70 mRNA, brain-derived neurotrophic factor mRNA, and cyclooxygenase-2 mRNA in rat brain following seizures induced by systemic administration of kainic acid** *Brain Res* 1998, **804**:212-223.
28. Tocco G, Freire-Moar J, Schreiber SS, Sakhi SH, Aisen PS and Pasinetti GM: **Maturation regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease** *Exp Neurol* 1997, **144**:339-349.
29. Facino RM, Carini M and Aldini G: **Antioxidant activity of nimesulide and its main metabolites** *Drugs* 1993, **46**(Suppl 1):15-21.
30. Maffei-Facino R, Carini M, Aldini G, Saibene L and Maccocchi A: **Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model** *Int J Tissue React* 1993, **15**:225-234.
31. Melchiorri D, Reiter RJ, Chen LD, Sewerynek E and Nistico G: **Melatonin affords protection against kainate-induced in vitro lipid peroxidation in brain** *Eur J Pharmacol* 1996, **305**:239-242.
32. Esterbauer H and Cheeseman KH: **Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonena** *Meth Enzymol* 1990, **186**:407-421.
33. Sedlak J and Lindsay RH: **Estimation of total protein-bound and nonprotein sulfhydryl groups in tissue with Ellman's reagent** *Anal Biochem* 1968, **25**:192-205.
34. Spector T: **Refinement of the Coomassie Blue method of protein quantification** *Anal Biochem* 1978, **86**:142-146.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

